COVID-19 - November 17, 2021
Pfizer seeks Emergency Use Authorization for PAXLOVID
Pfizer is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID, for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. This submission to the U.S. Food and Drug Administration (FDA) includes clinical data from the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 […]
COVID-19 - August 2, 2021
Pfizer-BioNTech’s second dose triggers powerful immune response
A new study has revealed that the second dose of the Pfizer-BioNTech COVID-19 vaccine triggers massive immune response against the virus. Researchers at the Stanford University School of Medicine, US, have investigated the effect of the second Pfizer-BioNTech COVID-19 vaccine dose in the human body. The study, published in Nature, was designed to find out […]
COVID-19 - May 31, 2021
Study of Pfizer’s pneumococcal conjugate vaccine candidate + 3rd dose COVID-19 vaccine
The first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the co-administration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine. The primary objective in the trial is to describe safety when both vaccines are […]
COVID-19 - April 19, 2021
Pfizer/BioNTech to supply the EU with 100 million additional vaccine doses
Pfizer and BioNTech have announced they will supply an additional 100 million doses of COMIRNATY, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a result of the European Commission’s (EC) decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced […]
COVID-19 - March 25, 2021
Pfizer initiates study of new antiviral therapeutic agent against SARS-CoV-2
Pfizer is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2. This Phase 1 trial is being conducted in the United States. The oral antiviral clinical candidate PF-07321332, […]
COVID-19 - March 1, 2021
Pfizer and BioNTech to evaluate COVID-19 booster and new vaccine variants
Pfizer and BioNTech have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in […]
